Fujian Shengdi Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of HRS-9057 in Patients With Heart Failure and Volume Overload

Phase 1

Not yet recruiting

Conditions: Heart Failure With Volume Overload

Interventions: Drug: HRS-9057
Drug: Tolvaptan

First Posted Date: 2024-07-18

Last Posted Date: 2024-07-18

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT06506994

Locations: 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Overweight or Obese, Type 2 Diabetes

Interventions: Drug: HRS9531 tablets

First Posted Date: 2024-07-17

Last Posted Date: 2024-07-17

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 144

Registration Number: NCT06506175

Locations: 🇨🇳
The affiliated hospital of Qingdao University, Qingdao, Shandong, China

A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults

Phase 2

Not yet recruiting

Conditions: Preventing of Postoperative Nausea and Vomiting in Adults

Interventions: Drug: HRS5580
Drug: Ondansetron
Drug: blank preparation

First Posted Date: 2024-06-26

Last Posted Date: 2024-06-26

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 232

Registration Number: NCT06475846

Locations: 🇨🇳
Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial

Phase 1

Recruiting

Conditions: Acute Ischemic Stroke

Interventions: Drug: 0.9% sodium chloride injection
Drug: HRS-7450

First Posted Date: 2024-06-07

Last Posted Date: 2024-12-10

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 62

Registration Number: NCT06447415

Locations: 🇨🇳
The First Affiliated Hospital of Sun Yat sen University, Guangzhou, Guangdong, China

A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

Phase 1

Recruiting

Conditions: Overweight or Obesity; Type 2 Diabetes

Interventions: Drug: Placebo
Drug: HRS9531

First Posted Date: 2024-05-30

Last Posted Date: 2024-06-21

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 92

Registration Number: NCT06435676

Locations: 🇨🇳
The Second Hospital Of Anhui medical University, Hefei, Anhui, China

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Phase 2

Recruiting

Conditions: Chronic Hepatitis B

Interventions: Drug: HRS-5635 Injection

First Posted Date: 2024-05-22

Last Posted Date: 2024-06-24

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 165

Registration Number: NCT06425341

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Phase 3

Recruiting

Conditions: Overweight or Obesity

Interventions: Drug: HRS9531 injection
Drug: Placebo

First Posted Date: 2024-05-02

Last Posted Date: 2024-05-30

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 540

Registration Number: NCT06396429

Locations: 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

Phase 2

Recruiting

Conditions: Heart Failure With Preserved Ejection Fraction

Interventions: Drug: HRS9531
Drug: Placebo

First Posted Date: 2024-04-30

Last Posted Date: 2024-05-20

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 200

Registration Number: NCT06391710

Locations: 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China

A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects

Phase 1

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: HRS9531

First Posted Date: 2024-02-07

Last Posted Date: 2024-03-06

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT06246175

Locations: 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Phase 2

Recruiting

Conditions: Patients With Candidemia and/or Invasive Candidiasis

Interventions: Drug: HRS9432
Drug: Caspofungin Acetate for Injection

First Posted Date: 2024-01-08

Last Posted Date: 2024-11-18

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT06194201

Locations: 🇨🇳
The First Affiliated Hospital Of University Of South China, Hengyang, Hunan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy